Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

• Status: RECRUITING
• Trial end date: 2031-07-01

Summary

This is a multicenter, open-label, Phase II clinical trial to evaluate the efficacy and safety of Trastuzumab Rezetecan (SHR-A1811) or in combination with Adebrelimab (SHR-1316) for HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC).

• Phase: PHASE2

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborators: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The fifth Affiliated Hospital of Guangzhou Medcial University; The Second Affiliated Hospital of Kunming Medical University; Tongji Medical Collage of Huazhong University of Science & Technology